PT865294E - Processo para a reducao ou a manutencao de niveis reduzidos de lipidos no sangue utilizando composicoes de proteina ob - Google Patents

Processo para a reducao ou a manutencao de niveis reduzidos de lipidos no sangue utilizando composicoes de proteina ob

Info

Publication number
PT865294E
PT865294E PT96926873T PT96926873T PT865294E PT 865294 E PT865294 E PT 865294E PT 96926873 T PT96926873 T PT 96926873T PT 96926873 T PT96926873 T PT 96926873T PT 865294 E PT865294 E PT 865294E
Authority
PT
Portugal
Prior art keywords
lipids
blood
reducing
reduced levels
maintaining reduced
Prior art date
Application number
PT96926873T
Other languages
English (en)
Inventor
Mary Ann Pelleymounter
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PT865294E publication Critical patent/PT865294E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT96926873T 1995-08-17 1996-08-02 Processo para a reducao ou a manutencao de niveis reduzidos de lipidos no sangue utilizando composicoes de proteina ob PT865294E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51626395A 1995-08-17 1995-08-17

Publications (1)

Publication Number Publication Date
PT865294E true PT865294E (pt) 2004-07-30

Family

ID=24054813

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96926873T PT865294E (pt) 1995-08-17 1996-08-02 Processo para a reducao ou a manutencao de niveis reduzidos de lipidos no sangue utilizando composicoes de proteina ob

Country Status (13)

Country Link
US (1) US20020147142A1 (pt)
EP (1) EP0865294B1 (pt)
JP (1) JP4173913B2 (pt)
AT (1) ATE259650T1 (pt)
AU (1) AU6688896A (pt)
CA (1) CA2229450A1 (pt)
DE (1) DE69631605T2 (pt)
DK (1) DK0865294T3 (pt)
ES (1) ES2216055T3 (pt)
MX (1) MX9801159A (pt)
PT (1) PT865294E (pt)
WO (1) WO1997006816A1 (pt)
ZA (1) ZA966798B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
EP0833835A4 (en) * 1995-06-22 1999-05-26 Lilly Co Eli OBESITY PROTEIN INTERMEDIATE PRODUCTS, THEIR PRODUCTION AND USE
US5830450A (en) * 1996-06-19 1998-11-03 Lallone; Roger L. Compositions of leptin bound to an apolipoprotein
US7332338B2 (en) 1996-10-04 2008-02-19 Lexicon Pharmaceuticals, Inc. Vectors for making genomic modifications
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6436707B1 (en) 1998-03-27 2002-08-20 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
US6808921B1 (en) 1998-03-27 2004-10-26 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
ES2228082T3 (es) * 1998-08-10 2005-04-01 Amgen Inc. Conjugados dextrano-leptina, composiciones farmaceuticas y metodos relacionados.
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
AU782230B2 (en) 1999-09-22 2005-07-14 Serono Genetics Institute S.A. Methods of screening for compounds that modulate the LSR-leptin interaction and their use in the prevention and treatment of obesity-related diseases
ATE475094T1 (de) 2001-10-22 2010-08-15 Amgen Inc Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
GB0307367D0 (en) * 2003-03-29 2003-05-07 Twg Composition and method for treating the gastro-intestinal tract
EP1462116A1 (en) * 2003-03-29 2004-09-29 Villitech SARL Composition for treating the gastrointestinal tract
JP2007517042A (ja) 2003-12-30 2007-06-28 デュレクト コーポレーション 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
DK1814590T4 (da) 2004-11-01 2014-02-24 Amylin Pharmaceuticals Llc Behandling af obesitet og beslægtede sygdomme.
US7629315B2 (en) * 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
EP2621519B1 (en) 2010-09-28 2017-06-28 Aegerion Pharmaceuticals, Inc. Leptin-abd fusion polypeptides with enhanced duration of action
DK2900230T3 (en) 2012-09-27 2018-11-12 Childrens Medical Ct Corp RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
SI3074033T1 (sl) 2013-11-26 2019-03-29 The Children's Medical Center Corporation Spojine za zdravljenje debelosti in postopki njihove uporabe
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
RS64850B1 (sr) 2016-09-12 2023-12-29 Amryt Pharmaceuticals Inc Metodi za detektovanje neutrališućih antitela na leptin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Also Published As

Publication number Publication date
US20020147142A1 (en) 2002-10-10
EP0865294B1 (en) 2004-02-18
AU6688896A (en) 1997-03-12
ATE259650T1 (de) 2004-03-15
EP0865294A1 (en) 1998-09-23
DK0865294T3 (da) 2004-06-28
MX9801159A (es) 1998-05-31
JP4173913B2 (ja) 2008-10-29
CA2229450A1 (en) 1997-02-27
ES2216055T3 (es) 2004-10-16
WO1997006816A1 (en) 1997-02-27
DE69631605D1 (de) 2004-03-25
JPH11511165A (ja) 1999-09-28
DE69631605T2 (de) 2005-01-05
ZA966798B (en) 1997-02-19

Similar Documents

Publication Publication Date Title
PT865294E (pt) Processo para a reducao ou a manutencao de niveis reduzidos de lipidos no sangue utilizando composicoes de proteina ob
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
ATE202940T1 (de) Mittel und methoden zur behandlung von plaque- krankheiten
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
EA200601059A1 (ru) Сложные моноэфиры пробукола для лечения сердечно-сосудистых и воспалительных заболеваний
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
BR9509269A (pt) Processo para tratar diabetes
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DK0764209T3 (da) Albuminekspression i gær
DE69635304D1 (de) Faenger fuer oxidantien
ES2168766T3 (es) Preparacion farmaceutica que incluye el propeptido vwf.
MX9401294A (es) Derivados de azolona sustituida
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
DE69635305D1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
DE69720064D1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
EA199900006A1 (ru) Препарат и способ для лечения застоной сердечной недостаточности
NO984198L (no) FremgangsmÕte for behandling av aggresjon
UA31401A (uk) Спосіб хірургічного лікування портальної гіпертензії
UA22009A (uk) Спосіб лікуваhhя сальпіhгоофориту
UA25252A (uk) Хірургічhий спосіб лікуваhhя захворюваhь артерій hижhіх кіhцівок